Abstract
Diabetic cardiomyopathy is a serious complication of diabetes and is associated with severe morbidity and mortality. Several new targets have been identified for diabetic cardiomyopathy. Oxidative stress plays an important role in diabetic cardiomyopathy and several anti-oxidants are reported to exhibit cardioprotective effects in diabetes. Histone deacetylases (HDAC) are group of enzymes involved in epigenetic regulation of genes and thereby exhibit varied effects. In addition to diabetic cardiomyopathy, HDACs are known to play a role in various diseases like cancer, neurological disorders, immune diseases etc. Documented evidences have suggests role of histone modifications in diabetic cardiomyopathy and hence HDACs serve as an important therapeutic target for diabetic cardiomyopathy. The present book chapter provides an overview of histone modifications in diabetic cardiomyopathy and exploring HDACs as therapeutic option for the same.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
